Literature DB >> 33552961

Mechanism and Molecular Network of RBM8A-Mediated Regulation of Oxaliplatin Resistance in Hepatocellular Carcinoma.

Rong Liang1, Jinyan Zhang1, Zhihui Liu1, Ziyu Liu1, Qian Li1, Xiaoling Luo2, Yongqiang Li1, Jiazhou Ye3, Yan Lin1.   

Abstract

RNA-binding motif protein 8A (RBM8A) is abnormally overexpressed in hepatocellular carcinoma (HCC) and involved in the epithelial-mesenchymal transition (EMT). The EMT plays an important role in the development of drug resistance, suggesting that RBM8A may be involved in the regulation of oxaliplatin (OXA) resistance in HCC. Here we examined the potential involvement of RBM8A and its downstream pathways in OXA resistance using in vitro and in vivo models. RBM8A overexpression induced the EMT in OXA-resistant HCC cells, altering cell proliferation, apoptosis, migration, and invasion. Moreover, whole-genome microarrays combined with bioinformatics analysis revealed that RBM8A has a wide range of transcriptional regulatory capabilities in OXA-resistant HCC, including the ability to regulate several important tumor-related signaling pathways. In particular, histone deacetylase 9 (HDAC9) emerged as an important mediator of RBM8A activity related to OXA resistance. These data suggest that RBM8A and its related regulatory pathways represent potential markers of OXA resistance and therapeutic targets in HCC.
Copyright © 2021 Liang, Zhang, Liu, Liu, Li, Luo, Li, Ye and Lin.

Entities:  

Keywords:  RNA-binding motif protein 8A; drug resistance; hepatocellular carcinoma; histone deacetylase 9; molecular network; oxaliplatin

Year:  2021        PMID: 33552961      PMCID: PMC7862710          DOI: 10.3389/fonc.2020.585452

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  54 in total

1.  Linear models and empirical bayes methods for assessing differential expression in microarray experiments.

Authors:  Gordon K Smyth
Journal:  Stat Appl Genet Mol Biol       Date:  2004-02-12

Review 2.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

3.  High expression of RBM8A predicts poor patient prognosis and promotes tumor progression in hepatocellular carcinoma.

Authors:  Rong Liang; Yan Lin; Jia-Zhou Ye; Xue-Xin Yan; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Hai-Hong Ye
Journal:  Oncol Rep       Date:  2017-02-15       Impact factor: 3.906

4.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

5.  Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin.

Authors:  Jun Li Ma; Shan Zeng; Yan Zhang; Gan Lu Deng; Hong Shen
Journal:  Tumour Biol       Date:  2015-11-27

6.  HULC and H19 Played Different Roles in Overall and Disease-Free Survival from Hepatocellular Carcinoma after Curative Hepatectomy: A Preliminary Analysis from Gene Expression Omnibus.

Authors:  Zongguo Yang; Yunfei Lu; Qingnian Xu; Bozong Tang; Cheol-Keun Park; Xiaorong Chen
Journal:  Dis Markers       Date:  2015-06-07       Impact factor: 3.434

7.  Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis.

Authors:  Federico Ávila-Moreno; Leonel Armas-López; Aldo M Álvarez-Moran; Zoila López-Bujanda; Blanca Ortiz-Quintero; Alfredo Hidalgo-Miranda; Francisco Urrea-Ramírez; R María Rivera-Rosales; Eugenia Vázquez-Manríquez; Erika Peña-Mirabal; José Morales-Gómez; Juan C Vázquez-Minero; José L Téllez-Becerra; Roberto Ramírez-Mendoza; Alejandro Ávalos-Bracho; Enrique Guzmán de Alba; Karla Vázquez-Santillán; Vilma Maldonado-Lagunas; Patricio Santillán-Doherty; Patricia Piña-Sánchez; Joaquin Zúñiga-Ramos
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

8.  Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway.

Authors:  Lui Ng; Ariel K M Chow; Johnny H W Man; Thomas C C Yau; Timothy M H Wan; Deepak N Iyer; Virginia H T Kwan; Ronnie T P Poon; Roberta W C Pang; Wai-Lun Law
Journal:  BMC Cancer       Date:  2018-06-01       Impact factor: 4.430

9.  Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway.

Authors:  Yuan Qin; Hui-Juan Liu; Meng Li; Deng-Hui Zhai; Yuan-Hao Tang; Lan Yang; Kai-Liang Qiao; Jia-Huan Yang; Wei-Long Zhong; Qiang Zhang; Yan-Rong Liu; Guang Yang; Tao Sun; Cheng Yang
Journal:  EBioMedicine       Date:  2018-11-02       Impact factor: 8.143

10.  LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.

Authors:  Hai Huang; Jie Chen; Cheng-Ming Ding; Xin Jin; Ze-Ming Jia; Jian Peng
Journal:  J Cell Mol Med       Date:  2018-03-30       Impact factor: 5.310

View more
  6 in total

1.  Molecular Insights and Prognosis Associated With RBM8A in Glioblastoma.

Authors:  Lei Wei; Chun Zou; Liechun Chen; Yan Lin; Lucong Liang; Beiquan Hu; Yingwei Mao; Donghua Zou
Journal:  Front Mol Biosci       Date:  2022-04-29

2.  Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients.

Authors:  Shenglan Huang; Dan Li; Lingling Zhuang; Jian Zhang; Jianbing Wu
Journal:  Front Med (Lausanne)       Date:  2022-05-24

3.  RBM8A Depletion Decreases the Cisplatin Resistance and Represses the Proliferation and Metastasis of Breast Cancer Cells via AKT/mTOR Pathway.

Authors:  Tao Song; Huazhou Zhang
Journal:  Breast J       Date:  2022-08-28       Impact factor: 2.269

Review 4.  Diverse Roles of the Exon Junction Complex Factors in the Cell Cycle, Cancer, and Neurodevelopmental Disorders-Potential for Therapeutic Targeting.

Authors:  Hannah Martin; Julian Rupkey; Shravan Asthana; Joy Yoon; Shray Patel; Jennifer Mott; Zifei Pei; Yingwei Mao
Journal:  Int J Mol Sci       Date:  2022-09-08       Impact factor: 6.208

5.  A Comprehensive Pan-Cancer Analysis of RBM8A Based on Data Mining.

Authors:  Nan Mei; Heyan Chen; Ni Zhao; Ye Yi; Chunli Li
Journal:  J Oncol       Date:  2021-07-06       Impact factor: 4.375

Review 6.  Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.

Authors:  Chun Yang; Stéphane Croteau; Pierre Hardy
Journal:  Cell Oncol (Dordr)       Date:  2021-07-27       Impact factor: 7.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.